Glaucoma: Epidemiology Forecast to 2030

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for glaucoma in the seven major markets: (7MM: The US, France, Germany, Italy, Spain, the UK, and Japan). In the 7MM, the total prevalent cases of primary open-angle glaucoma (POAG) will be 7,289,907 cases in 2020 growing at an Annual Growth Rate (AGR) of more than 2%. It is forecasted that all markets will see an increase in the total prevalent cases of POAG and PACG during the forecast period.

Glaucoma is a common, asymptomatic group of eye diseases that causes damage to the eye’s optic nerve, resulting in progressive, irreversible vision loss. Glaucoma is one of the leading causes of blindness worldwide, especially in elderly people. It is generally categorized as open-angle glaucoma (OAG), angle-closure glaucoma (ACG), or secondary glaucoma (SG). Although there are many types of glaucoma, the two most important types are OAG and ACG, with OAG accounting for approximately 80-90% of all glaucoma cases. OAG and ACG can also be classified as primary (primary open-angle glaucoma [POAG] or primary angle-closure glaucoma [PACG], respectively) or SG, depending on the cause.

In 2020, the US accounted for more than 30% of the total prevalent cases of NTG in the 7MM, with 2,909,797 cases. There were 2,480,076 cases of NTG in the 5EU combined of the cases in the 7MM in 2020. In 2020, Japan had 2,774,440 total prevalent cases, in the 7MM. In the 7MM, the number of total prevalent cases will grow at an Annual Growth Rate (AGR) of more than 0.50% cases by 2030.

Overview of Total Prevalent Cases of NTG, Men and Women, 7MM

For more insights on this report, download a free report sample

What are the market dynamics in the glaucoma epidemiology?

Glaucoma is a serious burden on health resources, and due to the rapidly aging population with comorbidities across countries, this is expected to increase further in the future. Studies have suggested that the prevalence of glaucoma (especially POAG) has been steadily increasing over the past decade but ascertaining this is difficult due to most cases remaining undiagnosed. It’s been expected that all markets will see an increase in the total prevalent cases and diagnosed prevalent cases of POAG and PACG during the forecast period.

There is also a general trend of the number of glaucoma cases increasing with age across the 7MM. There could be many reasons for the increasing prevalent cases, including a growing aging population, individuals with more comorbid conditions that worsen susceptibility, and asymptomatic cases that are detected at advanced levels or stages. Glaucoma blindness has increased even if the treatment on offer prevents the worsening of eye conditions. The primary reason for this is that most of the cases remain undiagnosed. The older population is at higher risk of glaucoma, and epidemiologists forecast that ages 70 years and older represent 60% of all POAG cases. This age group also has more comorbidities than younger age groups. Thus, patient management should rely on early recognition of at-risk patients (aging population with comorbidities), allowing correct therapeutic measures to be started rapidly.

Which are the key countries in the glaucoma epidemiology market?

In the 7MM, the US had the highest total prevalence of POAG in 2020 in men, whereas Japan had the lowest total prevalence in 2020. In the 7MM, France had the highest total prevalence of POAG in 2020 in women whereas Japan had the lowest total prevalence in 2020. The difference in prevalence between men and women was highest in France with the prevalence of POAG in women 0.85% higher than in men.

Similarly, in the 7MM, Japan had the highest total prevalence of PACG in 2020 in men whereas, the US had the lowest total prevalence in 2020. In the 7MM, Japan had the highest total prevalence of PACG in 2020 in women, whereas the US had the lowest total prevalence in 2020r. The difference in prevalence between men and women was highest in Italy with prevalence in women 0.72% higher than in men.

Glaucoma epidemiology market, by key country

For more about regional insights, download a free report sample

Market report scope

Scope

• Glaucoma Epidemiology Report and Model provide an overview of the risk factors and global trends of glaucoma in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• This report also includes a 10-year epidemiological forecast for the following segmentations in ≥40 years the 7MM: total prevalent cases and diagnosed prevalent cases of primary open-angle glaucoma (POAG) and primary angle-closure glaucoma (PACG), segmented by sex and age (40–49 years, 50–59 years, 60–69 years, 70–79 years, and ages 80 years and older). In addition, this report also provides a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of following glaucoma clinical types: normal-tension glaucoma (NTG), pre perimetric glaucoma (PPG), and secondary glaucoma (SG). The report also includes the diagnosed incident cases of acute PACG and diagnosed prevalent cases of acute and chronic PACG.
• The Glaucoma Epidemiology Report and Model were written and developed by Masters- and PhD-level epidemiologists.
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
• The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

• Develop business strategies by understanding the trends shaping and driving the global glaucoma market.
• Quantify patient populations in the global glaucoma market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying by identifying the age groups and sex that present the best opportunities for therapeutics in each of the markets covered.
• Understand the population of glaucoma clinical types such as POAG, PACG, NTG, PPG, and SG.